> top > projects > sentences > docs > PubMed:25347993 > annotations
sentences Home  

PubMed:25347993 JSONTXT 72 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-119 Sentence denotes Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.
T1 0-119 Sentence denotes Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.
T1 0-119 Sentence denotes Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.
TextSentencer_T2 120-172 Sentence denotes Lung cancer is the most common malignancy worldwide.
T2 120-172 Sentence denotes Lung cancer is the most common malignancy worldwide.
T2 120-172 Sentence denotes Lung cancer is the most common malignancy worldwide.
TextSentencer_T3 173-298 Sentence denotes Thus, there is a critical need for diagnostic biomarkers with adequate sensitivity and specificity for lung cancer detection.
T3 173-298 Sentence denotes Thus, there is a critical need for diagnostic biomarkers with adequate sensitivity and specificity for lung cancer detection.
T3 173-298 Sentence denotes Thus, there is a critical need for diagnostic biomarkers with adequate sensitivity and specificity for lung cancer detection.
TextSentencer_T4 299-433 Sentence denotes Glycans in glycoproteins are significantly altered in cancer, and may serve as a tool for identifying potential diagnostic biomarkers.
T4 299-433 Sentence denotes Glycans in glycoproteins are significantly altered in cancer, and may serve as a tool for identifying potential diagnostic biomarkers.
T4 299-433 Sentence denotes Glycans in glycoproteins are significantly altered in cancer, and may serve as a tool for identifying potential diagnostic biomarkers.
TextSentencer_T5 434-555 Sentence denotes Recent studies have reported changes in α-1-antitrypsin (A1AT) glycosylation in lung cancer serum, tissue and cell lines.
T5 434-555 Sentence denotes Recent studies have reported changes in α-1-antitrypsin (A1AT) glycosylation in lung cancer serum, tissue and cell lines.
T5 434-555 Sentence denotes Recent studies have reported changes in α-1-antitrypsin (A1AT) glycosylation in lung cancer serum, tissue and cell lines.
TextSentencer_T6 556-779 Sentence denotes In this study, a lectin microarray was used to detect glycosylation changes in serum A1AT from patients with lung adenocarcinoma (ADC), squamous cell lung cancer, small-cell lung cancer (SCLC) and benign pulmonary diseases.
T6 556-779 Sentence denotes In this study, a lectin microarray was used to detect glycosylation changes in serum A1AT from patients with lung adenocarcinoma (ADC), squamous cell lung cancer, small-cell lung cancer (SCLC) and benign pulmonary diseases.
T6 556-779 Sentence denotes In this study, a lectin microarray was used to detect glycosylation changes in serum A1AT from patients with lung adenocarcinoma (ADC), squamous cell lung cancer, small-cell lung cancer (SCLC) and benign pulmonary diseases.
TextSentencer_T7 780-945 Sentence denotes Differentially expressed glycosylated patterns of A1AT were identified by lectin arrays and were confirmed by lectin-based enzyme-linked immunosorbent assay (ELISA).
T7 780-945 Sentence denotes Differentially expressed glycosylated patterns of A1AT were identified by lectin arrays and were confirmed by lectin-based enzyme-linked immunosorbent assay (ELISA).
T7 780-945 Sentence denotes Differentially expressed glycosylated patterns of A1AT were identified by lectin arrays and were confirmed by lectin-based enzyme-linked immunosorbent assay (ELISA).
TextSentencer_T8 946-1336 Sentence denotes We found that galactosylated A1AT could distinguish non-small-cell lung cancer (NSCLC) from benign pulmonary diseases (AUC = 0.834); fucosylated A1AT showed exceptional capability in distinguishing ADC from benign diseases (AUC = 0.919) or other lung cancer subtypes (AUC = 0.844), and A1AT containing poly-LacNAc could detect SCLC from benign diseases (AUC = 0.905) or NSCLC (AUC = 0.707).
T8 946-1336 Sentence denotes We found that galactosylated A1AT could distinguish non-small-cell lung cancer (NSCLC) from benign pulmonary diseases (AUC = 0.834); fucosylated A1AT showed exceptional capability in distinguishing ADC from benign diseases (AUC = 0.919) or other lung cancer subtypes (AUC = 0.844), and A1AT containing poly-LacNAc could detect SCLC from benign diseases (AUC = 0.905) or NSCLC (AUC = 0.707).
T8 946-1336 Sentence denotes We found that galactosylated A1AT could distinguish non-small-cell lung cancer (NSCLC) from benign pulmonary diseases (AUC = 0.834); fucosylated A1AT showed exceptional capability in distinguishing ADC from benign diseases (AUC = 0.919) or other lung cancer subtypes (AUC = 0.844), and A1AT containing poly-LacNAc could detect SCLC from benign diseases (AUC = 0.905) or NSCLC (AUC = 0.707).
TextSentencer_T9 1337-1463 Sentence denotes The present study indicates that glycosylated patterns of A1AT may serve as potential biomarkers for detection of lung cancer.
T9 1337-1463 Sentence denotes The present study indicates that glycosylated patterns of A1AT may serve as potential biomarkers for detection of lung cancer.
T9 1337-1463 Sentence denotes The present study indicates that glycosylated patterns of A1AT may serve as potential biomarkers for detection of lung cancer.
TextSentencer_T10 1464-1567 Sentence denotes Further studies in larger sample sizes are necessary to validate the clinical utility of these markers.
T10 1464-1567 Sentence denotes Further studies in larger sample sizes are necessary to validate the clinical utility of these markers.
T10 1464-1567 Sentence denotes Further studies in larger sample sizes are necessary to validate the clinical utility of these markers.